An Analysis of the Efficacy of High Dose Isofosfamide Through Elastomer

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

NCT00864318 ·Status: COMPLETED ·Phase: PHASE2

Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

NCT03811886 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

NCT02784015 ·Status: UNKNOWN ·Phase: PHASE2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

NCT06465199 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Doxorubicin Hydrochloride Liposome Combined With Irinotecan (AI Regimen) Versus VIT Regimen in the Treatment of Relapsed and Refractory Pediatric Rhabdomyosarcoma: a Prospective, Open-label, Randomized Controlled, Multicenter, Phase II Clinical Study

NCT05457829 ·Status: RECRUITING ·Phase: PHASE2

Trabectedin and Irinotecan for Refractory Pediatric Sarcomas

NCT02509234 ·Status: UNKNOWN

A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma

NCT03015844 ·Status: AVAILABLE

Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma

NCT00876031 ·Status: COMPLETED ·Phase: PHASE3

Pharmacogenetically Based Dosing of Thiopurines in Childhood Acute Lymphoblastic Leukemia

NCT01678508 ·Status: COMPLETED

Therapeutic Response of Patients With Soft Tissue Sarcoma According to CHOI Criteria

NCT01650077 ·Status: COMPLETED

Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Rhabdomyosarcoma and Other Soft Tissue Sarcomas

NCT01216839 ·Status: UNKNOWN ·Phase: PHASE2

Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors

NCT05608148 ·Status: RECRUITING ·Phase: PHASE1

Phase I Clinical Trial of Anlotinib in Progressive, Recurrent, and Refractory Sarcoma in Children

NCT04659733 ·Status: UNKNOWN ·Phase: PHASE1

Exatecan Mesylate in Treating Children With Relapsed or Refractory Rhabdomyosarcoma

NCT00055939 ·Status: COMPLETED ·Phase: PHASE2

Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma

NCT01944982 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

NCT02756845 ·Status: COMPLETED ·Phase: PHASE1

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

NCT00001564 ·Status: COMPLETED ·Phase: PHASE2

Oxaliplatin for Children With Solid Tumors

NCT01558453 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children

NCT07137884 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Safety and Efficacy of OC-1 Therapy in Patients With R/R T-ALL/LL

NCT05679895 ·Status: RECRUITING ·Phase: PHASE1

A Multiple Ascending Dose Study of R1507 in Children and Adolescents With Advanced Solid Tumors.

NCT00560144 ·Status: COMPLETED ·Phase: PHASE1

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

NCT05634369 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB

NCT01125800 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy

NCT04478292 ·Status: RECRUITING ·Phase: PHASE3

"LANK-2": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia

NCT02074657 ·Status: COMPLETED ·Phase: PHASE2